Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study
Biopharmaceutics & Drug Disposition · 2023-04 · 44 (2) · 175-182
DOI: 10.1002/bdd.2354 ↗At a glance
Kohortenstudie in Biopharmaceutics & Drug Disposition, published online on 2023-03-28. Written by Liying Du and 8 co-authors. Institution: Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. Major MEDLINE topics: Anti-Bacterial Agents, Kidney Failure, Chronic. Cited 1 times so far (Crossref); 14 references. Funded by: The key project plan for health and medical science research in Hebei Provincial Health Commission.
Abstract (original language)
Blood concentration monitoring plays an important role in the rational use of norvancomycin. However, the reference interval for the norvancomycin plasma concentration in the treatment of infections in hemodialysis patients with end stage kidney disease is undefined. To determine the safe and effective interval for the norvancomycin plasma trough concentration, 39 patients treated with hemodialysis and norvancomycin were analyzed retrospectively. The norvancomycin plasma concentration before hemodialysis was tested as the trough concentration. The associations of the norvancomycin trough concentration with efficacy and adverse reactions were evaluated. No norvancomycin concentration above 20 μg/mL was detected. The trough concentration, but not the dose, had a significant effect on the anti‐infectious efficacy. Compared with the low norvancomycin trough concentration group (
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmacy, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- Department of Clinical Laboratory, Hebei General Hospital, Shijiazhuang, China.
- Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
ORCID profiles: Xinran Chen
Funding
- The key project plan for health and medical science research in Hebei Provincial Health Commission
Cite
APA
Du, L., Huo, L., Hou, J., Zhou, X., Liu, M., Guo, T., Wang, W., Chen, H., & Chen, X. (2023). Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study. Biopharmaceutics & Drug Disposition, 44(2), 175-182. https://doi.org/10.1002/bdd.2354
Vancouver
Du L, Huo L, Hou J, Zhou X, Liu M, Guo T, et al. Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study. Biopharmaceutics & Drug Disposition. 2023;44(2):175-182. doi:10.1002/bdd.2354
BibTeX
@article{Du2023,
author = {Du, Liying and Huo, Liman and Hou, Juan and Zhou, Xiajin and Liu, Mingfeng and Guo, Teng and Wang, Wei and Chen, Huihui and Chen, Xinran},
title = {Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study},
journal = {Biopharmaceutics & Drug Disposition},
year = {2023},
volume = {44},
number = {2},
pages = {175--182},
doi = {10.1002/bdd.2354}
}
EUVIMED